The adhesion of Aicarm to Global Heart Hub, and in particular the presence at the specific table "Cardiomyopathy Patient Council", brings the voice of Italy to an international body whose goal is to improve the diagnosis and treatment of cardiomyopathies. Annalisa and Matteo Pinciroli explain it well in one of the articles in this issue. The constant growth of the Association is the condition for having a stronger voice where it is necessary to intervene to create better living conditions and prospects for patients. The same goal we pursue in contacting research centers and nuclei of specific interest throughout Italy. I have recently been able to see the attention and interest in our activity in Liguria, Campania and Lombardy, where I was able to exchange experiences and involve senior medical and scientific professionals. A work of relationships and contacts that goes hand in hand with the expansion of the services we are organizing. We will let you know as soon as we are ready to go. Meanwhile, we inform you that the use of Mavacamten in the treatment of patients with hypertrophic obstructive cardiomyopathy has been approved in the USA, but not yet in Italy.
The President
Frank Cecchi